Regeneron Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Good morning. Welcome to Day 2 of Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst here at Barclays. I'm pleased to welcome Regeneron Pharmaceuticals to the stage to help us kick off the day.
Joining me on stage, Robert Landry, CFO of Regeneron; as well as Ryan Crowe, VP of IR. Before we get started on the Q&A, Ryan is going to a piece of lawyers, and then Bob can make some opening comments.
Thank you, Carter. Just very quickly, I'd like to remind you that remarks made today may include forward-looking statements about Regeneron. Any forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A description of material risks and uncertainties can be found in Regeneron's SEC filings. Regeneron does not undertake any obligation to update any forward-looking statements, whether
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
